

LETTER OF APPEAL FOR PRIOR AUTHORIZATION DENIAL GUIDE

WRITING A LETTER OF APPEAL FOR PRIOR AUTHORIZATION DENIAL*

A physician can write a letter of appeal when a patient's health insurance plan denies a prior authorization request. When doing so, the physician should refer to the plan's appeals guidelines, which may outline a specific process.

This resource provides information on the process of composing a letter of appeal for prior authorization denial, including a checklist and sample letter with information health plans often require.

Use of the information in this letter does not guarantee that the health plan will provide reimbursement for BIMZELX and is not intended to be a substitute for, or an influence on, the physician's independent medical judgment.

Letter of appeal considerations



- Include the patient's full name, plan identification number, date of birth, and case identification number
- The healthcare professional (HCP) should note the HCP's name and relationship to the patient, National Provider Identifier (NPI) number, specialty, address, telephone number, fax number, and date of submission
- State the patient's current diagnosis along with the specific International Classification of Diseases (ICD) code(s)
- The HCP should acknowledge that he/she is familiar with the plan's policy
- State the reason(s) why the prior authorization request was denied and why the HCP believes that decision should be reconsidered
- **Explain why BIMZELX is the preferred** and medically necessary treatment for the patient

- Document the patient's prior treatments for diagnosis, the duration and therapeutic outcome of each treatment, and the reason(s) why each was discontinued
- Provide a copy of the patient's medical records, including medical history, diagnosis, scoring forms, present-day condition and symptoms, photographs of affected areas, recent history of infection(s), allergies, and existing comorbidities
- Consider including the following supporting documentation:
 - A Letter of Medical Necessity
 - A copy of the denial letter and any medical notes in response to the denial
 - Clinical support for the HCP's recommendation (eg, clinical trial data, relevant peer-reviewed articles)

^{*}The information in this guide is presented for informational purposes only and is not intended to provide reimbursement or legal advice. HCPs are encouraged to contact third-party payers for specific information on their current coverage policies. For other questions, please call BIMZELX Navigate™ at 1-866-4-BIMZELX (1-866-424-6935).





LETTER OF APPEAL FOR PRIOR **AUTHORIZATION DENIAL GUIDE**

SAMPLE LETTER OF APPEAL FOR PRIOR AUTHORIZATION DENIAL

You may choose to use this template to assist in completing your request. Note: Exercise your medical judgment and discretion when providing a diagnosis and characterization of the patient's medical condition. Additionally, please ensure you have read and reviewed the health plan's relevant policies before certifying that you have done so.

SAMPLE LETTER OF APPEAL FOR PRIOR **AUTHORIZATION DENIAL**

You may choose to use this template to assist in completing your request. Note: Exercise your medical judgment and discretion when providing a diagnosis and characterization of the patient's medical condition. Use of the information in this letter does not quarantee that the health plan will provide reimbursement for BIMZELX and is not intended to be a substitute for, or an influence on, the physician's independent medical judgment.

[Name of health plan] [Appeals Department] [Mailing address]

Re: [Patient's name]

Plan ID: [Plan identification number]

DOB: [Date of birth]

Case ID: [Case identification number]

To whom it may concern,

I am writing to file an appeal regarding a prior authorization denial and to request reconsideration of coverage for BIMZELX® (bimekizumab-bkzx) for my patient, [patient's name].

[My office/patient's name] received a notice, dated [date of denial letter], indicating that prior authorization for coverage of BIMZELX for the treatment of [diagnosis], [ICD code(s)], has been denied by [name of health plan] for the following reasons: [insert reason(s) provided in the denial letter]. After reviewing this reasoning and reading your policy regarding the responsible management of drugs in this category, I continue to believe that BIMZELX is medically appropriate and necessary for [patient], as outlined below.

Patient's diagnosis, current condition, and medical history:

[Insert paragraph detailing your diagnosis and the patient's medical history pertaining to the use of BIMZELX. Examples of information to include are:

- Patient's age/gender/length of time in your care
- Up-to-date clinical documentation
- Relevant test scores/results
- Present-day symptoms
- Area(s) of the body affected, including percent of body surface area (BSA) and any persistent troublesome areas to treat
- Recent history of infection(s), allergies, and existing comorbidities
- Current treatment for condition (if applicable) and reason(s) why this treatment is insufficient
- Impact on quality of life]

[Patient's name] has attempted the below treatment(s) in the past for [diagnosis], but those trials have failed due to [inadequate efficacy, lack of tolerability, etc].

Past Treatment(s)	Start/Stop Dates	Therapeutic Outcome	Reason(s) for Discontinuing
[Drug name, strength, dosage, form]	[MM/YY] – [MM/YY]	[List treatment benefits and/or failures]	[List side effects, lack of efficacy, etc]
[Drug name, strength, dosage, form]	[MM/YY] – [MM/YY]	[List treatment benefits and/or failures]	[List side effects, lack of efficacy, etc]

In addition to this letter, I have enclosed a copy of [patient name's] medical records and a Letter of Medical Necessity. I have also included a copy of [journal article/clinical trial data/etc], which further supports why, in my professional opinion, BIMZELX is medically necessary for my patient's care and should be covered under [name of health plan].

Please contact me, [physician's name], at [physician's phone number] with any pending questions. Thank you for your time and consideration of this appeal.

[Physician's name and signature]

[Patient's name and signature]

[Physician's medical specialty] [Physician's NPI #] [Physician's practice name]

[Phone #1 [Fax #1

[Encl: Patient medical records, Letter of Medical Necessity, previous denial letter, medical notes in response to the denial, clinical support for this recommendation.]

NPI=National Provider Identifier.

Consider including supporting documentation, such as clinical evaluation, scoring forms, and photos of affected areas.



HELP CLEAR THE WAY WITH BIMZELX Navigate™*



BIMZELX Navigate helps make the treatment journey smooth from the start for your patients.

Start your patients on BIMZELX Navigate today



Here Is How!

- 1 Enroll your patients at BIMZELXhcp.com.
- Then, log in to the BIMZELX Navigate HCP Portal, click the "Add a Patient" button in the top right, and fill out the patient information.
- Fax a completed BIMZELX Navigate enrollment form to 844-628-3299.

Patients Get Support

- Easy enrollment and onboarding support for **streamlined product access—with no prior authorization (PA) needed** for eligible, commercially insured patients if there is a delay or denial in insurance coverage^{††}
- Eligible, commercially insured patients may pay only \$5 per dose once insurance coverage is approved or just \$15 per dose for up to 2 years while insurance coverage is pending[‡]
- Innovative tracking tools and resources available online at My Navigate Portal
- Nurse Navigators for assistance throughout the patient journey§

Nurse Navigators do not provide medical advice and will refer patients to their healthcare professional for any treatment-related questions.



^{*}The BIMZELX Navigate program is provided as a service of UCB and is intended to support the appropriate use of BIMZELX. The BIMZELX Navigate program may be amended or cancelled at any time without notice. Some program and eligibility restrictions may apply.

¹Prior to second dose, a PA will be needed.

[‡]For eligible, commercially insured patients only. Eligible patients who have a delay or denial of coverage may pay as little as \$15 per dose of BIMZELX for up to two years or until the patient's commercial insurance plan approves coverage, whichever comes first. Eligible, commercially insured patients may pay \$5 per dose. Please see full eligibility requirements and terms at BIMZELXhcp.com.



IMPORTANT SAFETY INFORMATION

INDICATION

BIMZELX is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

IMPORTANT SAFETY INFORMATION

Suicidal Ideation and Behavior

BIMZELX® (bimekizumab-bkzx) may increase the risk of suicidal ideation and behavior (SI/B). A causal association between treatment with BIMZELX and increased risk of SI/B has not been established. Prescribers should weigh the potential risks and benefits before using BIMZELX in patients with a history of severe depression or SI/B. Advise monitoring for the emergence or worsening of depression, suicidal ideation, or other mood changes. If such changes occur, advise to promptly seek medical attention, refer to a mental health professional as appropriate, and re-evaluate the risks and benefits of continuing treatment.

Infections

BIMZELX may increase the risk of infections. Do not initiate treatment with BIMZELX in patients with any clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing BIMZELX. Instruct patients to seek medical advice if signs or symptoms suggestive of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer BIMZELX until the infection resolves.

Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with BIMZELX. Avoid the use of BIMZELX in patients with active TB infection. Initiate treatment of latent TB prior to administering BIMZELX. Consider anti-TB therapy prior to initiation of BIMZELX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Closely monitor patients for signs and symptoms of active TB during and after treatment.

Liver Biochemical Abnormalities

Elevated serum transaminases were reported in clinical trials with BIMZELX. Test liver enzymes, alkaline phosphatase and bilirubin at baseline, periodically during treatment with BIMZELX and according to routine patient management. If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt BIMZELX until a diagnosis of liver injury is excluded. Permanently discontinue use of BIMZELX in patients with causally associated combined elevations of transaminases and bilirubin. Avoid use of BIMZELX in patients with acute liver disease or cirrhosis.

Inflammatory Bowel Disease

Cases of inflammatory bowel disease (IBD) have been reported in patients treated with IL-17 inhibitors, including BIMZELX. Avoid use of BIMZELX in patients with active IBD. During BIMZELX treatment, monitor patients for signs and symptoms of IBD and discontinue treatment if new onset or worsening of signs and symptoms occurs.

Immunizations

Prior to initiating therapy with BIMZELX, complete all age-appropriate vaccinations according to current immunization guidelines. Avoid the use of live vaccines in patients treated with BIMZELX.

MOST COMMON ADVERSE REACTIONS

Most common adverse reactions (\geq 1%) are upper respiratory infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, Herpes Simplex Infections, acne, folliculitis, other Candida infections, and fatigue.

Please click to access the full Prescribing Information, or visit BIMZELXhcp.com.





LETTER OF APPEAL FOR PRIOR AUTHORIZATION DENIAL GUIDE

SAMPLE LETTER OF APPEAL FOR PRIOR AUTHORIZATION DENIAL

You may choose to use this template to assist in completing your request. Note: Exercise your medical judgment and discretion when providing a diagnosis and characterization of the patient's medical condition. Use of the information in this letter does not guarantee that the health plan will provide reimbursement for BIMZELX and is not intended to be a substitute for, or an influence on, the physician's independent medical judgment.

[Date]

[Name of health plan] [Appeals Department]

[Mailing address]

Re: [Patient's name]

Plan ID: [Plan identification number]

DOB: [Date of birth]

Case ID: [Case identification number]

To whom it may concern,

I am writing to file an appeal regarding a prior authorization denial and to request reconsideration of coverage for BIMZELX® (bimekizumab-bkzx) for my patient, [patient's name].

[My office/patient's name] received a notice, dated [date of denial letter], indicating that prior authorization for coverage of BIMZELX for the treatment of [diagnosis], [ICD code(s)], has been denied by [name of health plan] for the following reasons: [insert reason(s) provided in the denial letter]. After reviewing this reasoning and reading your policy regarding the responsible management of drugs in this category, I continue to believe that BIMZELX is medically appropriate and necessary for [patient], as outlined below.

Patient's diagnosis, current condition, and medical history:

[Insert paragraph detailing your diagnosis and the patient's medical history pertaining to the use of BIMZELX. Examples of information to include are:

- Patient's age/gender/length of time in your care
- Up-to-date clinical documentation
- Relevant test scores/results
- Present-day symptoms
- Area(s) of the body affected, including percent of body surface area (BSA) and any persistent troublesome areas to treat
- Recent history of infection(s), allergies, and existing comorbidities
- Current treatment for condition (if applicable) and reason(s) why this treatment is insufficient
- Impact on quality of life]

[Patient's name] has attempted the below treatment(s) in the past for [diagnosis], but those trials have failed due to [inadequate efficacy, lack of tolerability, etc].

Past Treatment(s)	Start/Stop Dates	Therapeutic Outcome	Reason(s) for Discontinuing
[Drug name, strength, dosage, form]	[MM/YY] – [MM/YY]	[List treatment benefits and/or failures]	[List side effects, lack of efficacy, etc]
[Drug name, strength, dosage, form]	[MM/YY] – [MM/YY]	[List treatment benefits and/or failures]	[List side effects, lack of efficacy, etc]

In addition to this letter, I have enclosed a copy of [patient name's] medical records and a Letter of Medical Necessity. I have also included a copy of [journal article/clinical trial data/etc], which further supports why, in my professional opinion, BIMZELX is medically necessary for my patient's care and should be covered under [name of health plan].

Please contact me, [physician's name], at [physician's phone number] with any pending questions. Thank you for your time and consideration of this appeal.

Sincerely,

[Physician's name and signature]

[Patient's name and signature]

[Physician's medical specialty] [Physician's NPI #] [Physician's practice name] [Phone #] [Fax #]

